Notice of Allowance for Significant POLB 001 Patent in United StatesNotice of Allowance for Immunomodulator II further strengthens robust intellectual…
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim…
EAACI Congress 2024 EAACI Congress 2024 https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy…
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI…
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB)…
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company…
Tribe Public Webinar with Indaptus Therapeutics Tribe Public Webinar with Indaptus Therapeutics “Fully Engaging The Human Immune System To Cure…
Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to…
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided…